top of page

Zotarolimus: A Novel Drug-Eluting Stent for Vascular Restoration

Vascular diseases are a significant cause of morbidity and mortality worldwide. Coronary artery disease is one of the most common forms of vascular disease, and percutaneous coronary intervention (PCI) is a widely used treatment option. Drug-eluting stents (DES) have revolutionized the field of interventional cardiology, but they have limitations such as delayed healing, late stent thrombosis, and incomplete endothelialization. In this context, Zotarolimus, a novel drug-eluting stent, has emerged as a promising solution. In this article, we will explore the features, benefits, and clinical evidence of Zotarolimus.


Zotarolimus is a cytostatic agent that inhibits the proliferation of smooth muscle cells. It was first synthesized in the 1990s by Wyeth Pharmaceuticals, and its efficacy as a drug-eluting stent has been investigated in several clinical trials. Zotarolimus is a derivative of sirolimus, which is a widely used immunosuppressant in transplant medicine, and it has a similar mechanism of action. However, Zotarolimus has a shorter half-life, which allows for faster healing of the arterial wall after stent implantation.

Features of Zotarolimus

Zotarolimus is delivered through a polymer-based coating on a metallic stent scaffold. The polymer coating is designed to release the drug over a period of time to prevent restenosis. The stent scaffold is made of cobalt-chromium alloy, which provides excellent radial strength and conformability to the vessel wall. The stent design includes a unique abluminal reservoir that allows for sustained drug release and reduces the risk of thrombosis.

Benefits of Zotarolimus

Zotarolimus has several advantages over other drug-eluting stents. Firstly, it has a lower risk of stent thrombosis, which is a serious complication of DES. This is due to the abluminal reservoir design that ensures sustained drug release and promotes endothelialization. Secondly, Zotarolimus has a faster healing time, which reduces the risk of late adverse events such as restenosis. Thirdly, Zotarolimus has shown excellent clinical outcomes in several trials, indicating its superior efficacy and safety compared to other DES.

Clinical Evidence of Zotarolimus

Several clinical trials have investigated the efficacy and safety of Zotarolimus. The Endeavor clinical trial was one of the first trials to demonstrate the superiority of Zotarolimus over a bare-metal stent. The trial included 1,197 patients with de novo native coronary artery lesions and showed a significant reduction in target lesion revascularization (TLR) and major adverse cardiac events (MACE) with Zotarolimus compared to the control group.

The Resolute clinical trial investigated the efficacy and safety of Zotarolimus-eluting stents in patients with diabetes. The trial included 1,402 patients and showed a significant reduction in TLR and MACE with Zotarolimus compared to the control group. The trial also demonstrated the superiority of Zotarolimus over other DES such as paclitaxel-eluting stents.

The SORT OUT VI trial compared Zotarolimus-eluting stents with other DES in patients with complex lesions. The trial included 2,999 patients and showed a significant reduction in TLR and MACE with Zotarolimus compared to other DES such as everolimus-eluting stents and biolimus-eluting stents. The trial also showed a lower risk of stent thrombosis with Zotarolimus.


Zotarolimus is a promising drug-eluting stent that has shown excellent clinical outcomes in several trials. Its unique features such as the abluminal reservoir design and faster healing time make it a superior option compared to other DES. Zotarolimus has the potential to revolutionize the field of interventional cardiology and improve the quality of life for patients with coronary artery disease.

1 view

Recent Posts

See All

Catalpol: A Potential Treatment for Diabetic Nephropathy

Introduction Diabetic nephropathy (DN) is a common complication of diabetes, characterized by abnormal angiogenesis of glomerular endothelial cells (GECs) and macrophage infiltration Galectin-3, a pr


bottom of page